Akèy › Kansè nan tete › Missouri › Kansas City
Etid klinik pou Kansè nan tete nan Kansas City, MO
34 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Kansas City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Saint Luke's Hospital of Kansas City, Kansas City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- University of Kansas Cancer Center, Westwood · 5 mi lwen
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- HCA Midwest Division, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- Saint Luke's Cancer Institute, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- St. Lukes Hospital of Kansas City, Kansas City
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Ap rekriteFaz 3
- The University of Kansas Cancer Center, Westwood · 5 mi lwen
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Saint Luke's Cancer Institute, Kansas City
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Ap rekriteFaz 1/2
- Saint Luke's Hospital of Kansas City, Kansas City
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Saint Luke's Cancer Institute, Kansas City
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Ap rekriteFaz 2
- HCA Midwest Division, Kansas City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- HCA Midwest Health, Kansas City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- ak 1 plis
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- ak 2 plis
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- University of Kansas Cancer Center - North, Kansas City
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Saint Luke's Cancer Institute, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of Kansas Medical Center (KUMC), Westwood · 5 mi lwen
HER2-positive Breast Cancer Registry
Ap rekriteEtid obsèvasyon
- The University of Kansas Cancer Center, Westwood · 5 mi lwen
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Saint Luke's Cancer Institute, Kansas City
Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- ak 1 plis
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Saint Luke's Cancer Institute, Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · 5 mi lwen
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
Ap rekriteFaz 2
- The University of Kansas Cancer Center - North, Kansas City
- KUCC - Briarcliff, Westwood · 5 mi lwen
- KUCC - Olathe, Westwood · 5 mi lwen
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Saint Luke's Hospital of Kansas City, Kansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mi lwen
- ak 1 plis
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Ap rekriteFaz 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi lwen
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- ak 1 plis
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- Saint Luke's Hospital of Kansas City, Kansas City
- University of Kansas Cancer Center, Westwood · 5 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Kansas City
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- Truman Medical Centers, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · 2 mi lwen
- ak 1 plis
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Kansas City
- Kansè Poumon ki pa ti selil31 etid
- Ensifizyans kadyak25 etid
- Kansè (tout kalite)21 etid
- Kansè poumon19 etid
- Kansè kolorektal16 etid
- Kansè Metastatik15 etid
- Leksemi mieloïd egi15 etid
- Kansè pwostat14 etid
- Kansè ovè11 etid
- Obèsite11 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.